Renaissance Technologies LLC Sells 125,697 Shares of iCAD, Inc. (NASDAQ:ICAD)

Renaissance Technologies LLC cut its position in shares of iCAD, Inc. (NASDAQ:ICAD - Free Report) by 20.9% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 475,593 shares of the technology company's stock after selling 125,697 shares during the quarter. Renaissance Technologies LLC owned 1.79% of iCAD worth $870,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. First Eagle Investment Management LLC boosted its position in shares of iCAD by 6.1% in the fourth quarter. First Eagle Investment Management LLC now owns 716,161 shares of the technology company's stock worth $1,311,000 after acquiring an additional 41,000 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of iCAD by 6.6% in the 4th quarter. Geode Capital Management LLC now owns 276,493 shares of the technology company's stock valued at $506,000 after purchasing an additional 17,059 shares in the last quarter. Perritt Capital Management Inc increased its stake in iCAD by 1.9% during the fourth quarter. Perritt Capital Management Inc now owns 189,100 shares of the technology company's stock valued at $346,000 after purchasing an additional 3,600 shares during the last quarter. Summit Trail Advisors LLC acquired a new stake in shares of iCAD during the 4th quarter worth approximately $214,000. Finally, Wells Fargo & Company MN increased its holdings in shares of iCAD by 51.3% in the 4th quarter. Wells Fargo & Company MN now owns 39,542 shares of the technology company's stock worth $72,000 after acquiring an additional 13,402 shares during the period. Institutional investors and hedge funds own 24.61% of the company's stock.

iCAD Price Performance

NASDAQ:ICAD traded down $0.02 during trading hours on Monday, reaching $3.48. 345,204 shares of the stock were exchanged, compared to its average volume of 384,286. The firm has a 50 day moving average of $2.40 and a 200 day moving average of $2.26. iCAD, Inc. has a twelve month low of $1.18 and a twelve month high of $3.78. The stock has a market cap of $95.23 million, a PE ratio of -26.77 and a beta of 1.78.

iCAD (NASDAQ:ICAD - Get Free Report) last posted its earnings results on Wednesday, March 19th. The technology company reported ($0.03) earnings per share for the quarter, topping analysts' consensus estimates of ($0.05) by $0.02. The business had revenue of $5.41 million for the quarter, compared to analyst estimates of $4.72 million. iCAD had a negative return on equity of 15.65% and a negative net margin of 17.81%.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on ICAD shares. BTIG Research downgraded shares of iCAD from a "buy" rating to a "neutral" rating in a report on Wednesday, April 16th. Laidlaw restated a "hold" rating on shares of iCAD in a report on Thursday, April 17th. StockNews.com began coverage on shares of iCAD in a research note on Sunday. They set a "sell" rating for the company. Finally, Craig Hallum cut shares of iCAD from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, April 16th.

About iCAD

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.